Anti-tumoral and anti-angiogenic effects of low-diluted phenacetinum on melanoma - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Frontiers in Oncology Année : 2021

Anti-tumoral and anti-angiogenic effects of low-diluted phenacetinum on melanoma

Résumé

Melanoma is the most aggressive form of skin cancer and the most rapidly expanding cancer in terms of worldwide incidence. If primary cutaneous melanoma is mostly treated with a curative wide local excision, malignant melanoma has a poor prognosis and needs other therapeutic approaches. Angiogenesis is a normal physiological process essential in growth and development, but it also plays a crucial role in crossing from benign to advanced state in cancer. In melanoma progression, angiogenesis is widely involved during the vertical growth phase. Currently, no anti-angiogenic agents are efficient on their own, and combination of treatments will probably be the key to success. In the past, phenacetin was used as an analgesic to relieve pain, causing side effects at large dose and tumor-inducing in humans and animals. By contrast, Phenacetinum low-dilution is often used in skin febrile exanthema, patches profusely scattered on limbs, headache, or flushed face without side effects. Herein are described the in vitro, in vivo, and ex vivo anti-angiogenic and anti-tumoral potentials of Phenacetinum low-dilution in a B16F1 tumor model and endothelial cells. We demonstrate that low-diluted Phenacetinum inhibits in vivo tumor growth and tumor vascularization and thus increases the survival time of B16F1 melanoma induced-C57BL/6 mice. Moreover, Phenacetinum modulates the lung metastasis in a B16F10 induced model. Ex vivo and in vitro, we evidence that low-diluted Phenacetinum inhibits the migration and the recruitment of endothelial cells and leads to an imbalance in the pro-tumoral macrophages and to a structural malformation of the vascular network. All together these results demonstrate highly hopeful anti-tumoral, anti-metastatic, and anti-angiogenic effects of Phenacetinum low-dilution on melanoma. Continued studies are needed to preclinically validate Phenacetinum low-dilution as a complementary or therapeutic strategy for melanoma treatment.
Fichier principal
Vignette du fichier
fonc-11-597503.pdf (9.32 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03157446 , version 1 (04-03-2021)

Licence

Paternité

Identifiants

Citer

Camille Fuselier, Sandrine Quemener, Eleonore Dufay, Camille Bour, Camille Boulagnon-Rombi, et al.. Anti-tumoral and anti-angiogenic effects of low-diluted phenacetinum on melanoma. Frontiers in Oncology, 2021, 11, pp.597503. ⟨10.3389/fonc.2021.597503⟩. ⟨hal-03157446⟩
184 Consultations
24 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More